Cargando…
BFL-1 expression determines the efficacy of venetoclax in MYC+/BCL2+ double hit lymphoma
Autores principales: | Esteve-Arenys, Anna, Roue, Gael |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5978438/ https://www.ncbi.nlm.nih.gov/pubmed/29854869 http://dx.doi.org/10.18632/oncoscience.402 |
Ejemplares similares
-
Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors
por: Li, Weiping, et al.
Publicado: (2019) -
Targeting MYC and BCL2 by a natural compound for “double‐hit” lymphoma
por: Liu, Xiaoqian, et al.
Publicado: (2022) -
Targeting BCL2 with venetoclax is a promising therapeutic strategy for “double-proteinexpression” lymphoma with MYC and BCL2 rearrangements
por: Uchida, Akiko, et al.
Publicado: (2019) -
Double-hit lymphoma (rearrangements of MYC, BCL-2) during pregnancy: A case report
por: Xie, Fan, et al.
Publicado: (2021) -
Double‑hit primary lymphoma (MYC and BCL2) in the bilateral ovary: A case report
por: Zhang, Yan, et al.
Publicado: (2023)